 
 |
|
Nano-Particle Lung Treatments
Date: November 10, 2009
Client: Savara Pharmaceuticals
Summary: Dr. Moria Gunn sits down with Savara Pharmaceuticals executive chairman, Rob Neville, to discuss their innovative NanoCluster technology. |
|
|
|
 |
|
Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Date: November 25, 2009
Client: Cempra Pharmaceuticals Inc.
Summary: CHAPEL HILL, N.C., Nov. 25 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Piper Jaffray 21st Annual Health Care Conference at 8:50 a.m. EST, December 1, 2009, at The New York Palace Hotel in New York City.
|
|
|
|
 |
|
Pluristem Therapeutics Presents Three Month Follow-Up Data from First Patient to Receive Placental Derived PLX-PAD at Two Meetings in Germany and France
Date:November 19, 2009
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, Israel--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) today announced that it will present three month follow-up data from the first patient to receive PLX-PAD at both the 1st Annual Conference of the German-Israeli Life Science Committee at the Life Science Center in Düsseldorf, Germany and at the DigestScience Congress in Lille, France. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
|
|
|
|
|
|
|
Pluristem Therapeutics Announces Three Month Follow-Up Data from the First Patient to Receive PLX-PAD
Data Suggests PLX-PAD is Safe, with Noted Improvement in Measured Efficacy Parameters
Date: November 17, 2009
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, Israel--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
|
|
|
|
|
|
|
Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
Date: November 13, 2009
Client: Cempra Pharmaceuticals Inc.
Summary: Chapel Hill, N.C., Nov. 13, 2009 - Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009 at 9:25 a.m. EST at The St. Regis Hotel in New York City. Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs for the treatment of drug-resistant pathogens including MRSA.
|
|
|
|
 |
|
Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th
Date: November 6, 2009
Client: Helix BioPharma Corp.
Summary: AURORA, Ontario, Nov. 6 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on November 10th, 2009.
|
|
|
|
|
|
|
Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
Date: November 5, 2009
Client: Helix BioPharma Corp.
Summary: AURORA, Ontario, Nov. 5 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
|
|
|
|
 |
|
Aerovance Completes Patient Enrollment in Phase 2b Clinical Trial of Aerovant™ for Treatment of Uncontrolled Asthma
Date: November 4, 2009
Client: Aerovance Inc.
Summary: BERKELEY, Calif., Nov. 3, 2009 – Aerovance Inc. today announced it has completed patient enrollment in a Phase 2b clinical trial of the inhaled dry powder formulation of Aerovant for the treatment of uncontrolled asthma. Top-line results are expected by the second quarter of 2010.
|
|
|
|
|
